Vanda Pharmaceuticals (NASDAQ:VNDA) Shares Cross Above Two Hundred Day Moving Average - Should You Sell?

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $4.60 and traded as high as $5.55. Vanda Pharmaceuticals shares last traded at $5.49, with a volume of 687,772 shares.

Analyst Ratings Changes

VNDA has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vanda Pharmaceuticals in a report on Wednesday, October 8th. HC Wainwright reissued a "buy" rating and set a $20.00 target price on shares of Vanda Pharmaceuticals in a research note on Thursday, August 21st. Finally, Wall Street Zen cut shares of Vanda Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research note on Saturday, August 2nd. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $16.50.

Vanda Pharmaceuticals Stock Performance

The stock has a market cap of $324.40 million, a price-to-earnings ratio of -4.86 and a beta of 0.74. The company's 50 day simple moving average is $4.87 and its 200 day simple moving average is $4.60.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.12). The company had revenue of $52.59 million for the quarter, compared to analyst estimates of $54.77 million. Vanda Pharmaceuticals had a negative net margin of 32.90% and a negative return on equity of 12.89%. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS. Sell-side analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Several hedge funds have recently made changes to their positions in VNDA. Linden Thomas Advisory Services LLC acquired a new position in shares of Vanda Pharmaceuticals in the 1st quarter worth approximately $49,000. Bailard Inc. acquired a new position in shares of Vanda Pharmaceuticals in the 1st quarter worth approximately $103,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Vanda Pharmaceuticals in the 1st quarter worth approximately $875,000. GSA Capital Partners LLP grew its stake in shares of Vanda Pharmaceuticals by 88.0% in the 1st quarter. GSA Capital Partners LLP now owns 260,215 shares of the biopharmaceutical company's stock worth $1,194,000 after purchasing an additional 121,797 shares during the last quarter. Finally, XTX Topco Ltd grew its stake in shares of Vanda Pharmaceuticals by 378.3% in the 1st quarter. XTX Topco Ltd now owns 69,329 shares of the biopharmaceutical company's stock worth $318,000 after purchasing an additional 54,833 shares during the last quarter. Institutional investors and hedge funds own 88.14% of the company's stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.